FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer

FDA granted accelerated approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc.) for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news